vs

Side-by-side financial comparison of American Bitcoin Corp. (ABTC) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

American Bitcoin Corp. is the larger business by last-quarter revenue ($118.0M vs $85.1M, roughly 1.4× 4D Molecular Therapeutics, Inc.). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 151.5%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 296.9%).

Bitcoin is the first decentralized cryptocurrency. Based on a free-market ideology, bitcoin was invented in 2008 when an unknown person published a white paper under the pseudonym of Satoshi Nakamoto. Use of bitcoin as a currency began in 2009, with the release of its open-source implementation. From 2021 to 2025, El Salvador adopted it as legal tender currency before revoking it. As bitcoin is pseudonymous, its use by criminals has attracted the attention of regulators, leading to its ban by...

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

ABTC vs FDMT — Head-to-Head

Bigger by revenue
ABTC
ABTC
1.4× larger
ABTC
$118.0M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508748.5% gap
FDMT
8508900.0%
151.5%
ABTC
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
296.9%
ABTC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABTC
ABTC
FDMT
FDMT
Revenue
$118.0M
$85.1M
Net Profit
$19.4M
Gross Margin
49.1%
Operating Margin
-192.8%
17.3%
Net Margin
22.8%
Revenue YoY
151.5%
8508900.0%
Net Profit YoY
139.1%
EPS (diluted)
$-0.07
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABTC
ABTC
FDMT
FDMT
Q4 25
$118.0M
$85.1M
Q3 25
$64.2M
$90.0K
Q2 25
$1.4M
$15.0K
Q1 25
$1.6M
$14.0K
Q4 24
$46.9M
$1.0K
Q3 24
$11.6M
$3.0K
Q2 24
$5.5M
$5.0K
Q1 24
$7.5M
$28.0K
Net Profit
ABTC
ABTC
FDMT
FDMT
Q4 25
$19.4M
Q3 25
$3.5M
$-56.9M
Q2 25
$3.4M
$-54.7M
Q1 25
$-100.6M
$-48.0M
Q4 24
Q3 24
$-576.0K
$-43.8M
Q2 24
$-61.1M
$-35.0M
Q1 24
$230.4M
$-32.4M
Gross Margin
ABTC
ABTC
FDMT
FDMT
Q4 25
49.1%
Q3 25
56.0%
Q2 25
Q1 25
Q4 24
57.9%
Q3 24
4.2%
Q2 24
31.0%
Q1 24
35.4%
Operating Margin
ABTC
ABTC
FDMT
FDMT
Q4 25
-192.8%
17.3%
Q3 25
11.2%
-67983.3%
Q2 25
-162.1%
-396373.3%
Q1 25
-350.8%
-383007.1%
Q4 24
Q3 24
-87.8%
-1704400.0%
Q2 24
-106.4%
-849120.0%
Q1 24
-20.8%
-136200.0%
Net Margin
ABTC
ABTC
FDMT
FDMT
Q4 25
22.8%
Q3 25
5.4%
-63195.6%
Q2 25
249.2%
-364386.7%
Q1 25
-6458.5%
-342657.1%
Q4 24
Q3 24
-5.0%
-1461433.3%
Q2 24
-1107.2%
-699060.0%
Q1 24
3076.2%
-115717.9%
EPS (diluted)
ABTC
ABTC
FDMT
FDMT
Q4 25
$-0.07
$0.43
Q3 25
$0.06
$-1.01
Q2 25
$-0.07
$-0.98
Q1 25
$-0.09
$-0.86
Q4 24
$1.10
Q3 24
$-0.15
$-0.79
Q2 24
$-0.10
$-0.63
Q1 24
$-0.36
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABTC
ABTC
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$402.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$665.8M
$505.7M
Total Assets
$1.2B
$566.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABTC
ABTC
FDMT
FDMT
Q4 25
$402.7M
Q3 25
$305.1M
Q2 25
$750.0K
$293.2M
Q1 25
$367.0K
$321.4M
Q4 24
$850.0K
$424.9M
Q3 24
$478.0K
$501.9M
Q2 24
$1.4M
$541.9M
Q1 24
$1.9M
$525.9M
Stockholders' Equity
ABTC
ABTC
FDMT
FDMT
Q4 25
$665.8M
$505.7M
Q3 25
$575.5M
$369.0M
Q2 25
$339.7M
$420.9M
Q1 25
$115.8M
$469.7M
Q4 24
$1.0B
$510.6M
Q3 24
$697.5M
$552.9M
Q2 24
$614.3M
$588.3M
Q1 24
$696.8M
$600.6M
Total Assets
ABTC
ABTC
FDMT
FDMT
Q4 25
$1.2B
$566.7M
Q3 25
$1.2B
$424.0M
Q2 25
$6.2M
$473.6M
Q1 25
$9.0M
$515.7M
Q4 24
$1.1B
$560.4M
Q3 24
$7.5M
$604.0M
Q2 24
$11.4M
$620.1M
Q1 24
$17.8M
$629.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABTC
ABTC
FDMT
FDMT
Operating Cash FlowLast quarter
$-79.6M
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABTC
ABTC
FDMT
FDMT
Q4 25
$-79.6M
$28.6M
Q3 25
$-39.0M
$-46.5M
Q2 25
$-879.0K
$-43.4M
Q1 25
$-3.2M
$-47.8M
Q4 24
$-54.0M
$-134.6M
Q3 24
$-76.8M
$-29.4M
Q2 24
$201.0K
$-30.2M
Q1 24
$-983.0K
$-29.1M
Free Cash Flow
ABTC
ABTC
FDMT
FDMT
Q4 25
$28.5M
Q3 25
$-46.6M
Q2 25
$-1.4M
$-43.4M
Q1 25
$-48.4M
Q4 24
$-60.6M
$-138.4M
Q3 24
$-79.3M
$-31.2M
Q2 24
$-874.0K
$-30.6M
Q1 24
$-29.8M
FCF Margin
ABTC
ABTC
FDMT
FDMT
Q4 25
33.5%
Q3 25
-51765.6%
Q2 25
-104.4%
-289620.0%
Q1 25
-345635.7%
Q4 24
-129.2%
-13837100.0%
Q3 24
-683.2%
-1038966.7%
Q2 24
-15.8%
-611840.0%
Q1 24
-106421.4%
Capex Intensity
ABTC
ABTC
FDMT
FDMT
Q4 25
0.1%
Q3 25
101.1%
Q2 25
40.5%
440.0%
Q1 25
4507.1%
Q4 24
14.1%
378600.0%
Q3 24
21.6%
59266.7%
Q2 24
19.5%
6980.0%
Q1 24
2535.7%
Cash Conversion
ABTC
ABTC
FDMT
FDMT
Q4 25
1.47×
Q3 25
-11.21×
Q2 25
-0.26×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons